Real-world safety of ulinastatin: a post-marketing surveillance of 11,252 patients in China.

ABSTRACT:

Background

The safety assessment of ulinastatin can guide clinical practice. The present study aimed to investigate the real-world safety of ulinastatin in China.

Methods

This multicenter study retrospectively analyzed the post-marketing surveillance data of consecutive patients treated with ulinastatin between August 2014 and June 2017 in the general wards and the intensive care units (ICU) of nine hospitals in China. Adverse drug reactions/adverse drug events (ADRs/ADEs) were collected and evaluated in a post-marketing database.

Results

A total of 11,252 consecutive patients were included in the study: 7009 ICU patients and 4243 general ward patients. Eleven patients with ADRs/ADEs were observed, including nine ICU patients and two general ward patients. The clinica

SUBMITTER: Li J 

PROVIDER: S-EPMC9288682 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature